NCT01453504View on ClinicalTrials.gov

Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Hodgkin Lymphoma
Interventions
DRUG

DHAP

Dexamethasone, Cytarabine, Cisplatin

DRUG

Everolimus

Trial Locations (1)

Unknown

1st Dept. of Medicine, Cologne University Hospital, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT01453504 - Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter